Seer

What Seer does

Seer is a public proteomics company (NASDAQ: SEER) founded in 2017 and headquartered in Redwood City, California, that develops and commercializes the Proteograph Product Suite for deep, unbiased plasma proteome profiling. The platform is built around proprietary engineered magnetic-core nanoparticles with tuned surface chemistries that form reproducible protein coronas when introduced to biofluids, compressing the dynamic range of the plasma proteome. The integrated offering comprises consumable assay kits (Proteograph ONE, XT, DIRECT), the SP200 automation instrument capable of processing over 1,000 samples per week per instrument with under a five-hour runtime, and the cloud-based Proteograph Analysis Suite (PAS). Independent peer-reviewed benchmarks report up to 10x more protein groups than conventional direct-digest methods. Seer holds 23 validated patent claims on the core nanoparticle-enrichment technology, supported a Protein Discovery Catalog of 36,000+ identified proteins across 1,900+ biological pathways, and has accumulated 84 peer-reviewed publications including work in Nature Genetics and Nature.

Seer serves academic translational researchers, biopharmaceutical development teams, and biomarker discovery programs through three access pathways: direct instrument sales for high-volume in-house users, the Seer Technology Access Center (STAC) managed service for customers without mass spectrometry capabilities, and a global network of CRO service providers and Centers of Excellence. The revenue model combines capital equipment sales (SP100, SP200, SP200t instruments with 12-month warranties and optional service plans), recurring consumable revenue tied to the install base, bundled software licenses, and fee-for-service STAC projects priced on sample volume. Pricing is quote-based and not publicly disclosed. The instrument installed base reached 82 units by Q4 2025 (up 67% YoY), with consumable sample volumes up 69% YoY, though reported revenue declined 34% YoY in Q1 2026 amid academic funding pressure and NIH uncertainty.

The company went public in December 2020 and ended Q1 2026 with approximately $220 million in cash and investments against a market capitalization of approximately $101-111 million, meaning the equity trades below the cash position. Seer is currently navigating an activist proxy contest with the Radoff-JEC Group (7.7% owner), which has submitted three unsolicited acquisition proposals at $2.25-$2.40 per share, all rejected by the board. The board has separately filed an ITC complaint and federal lawsuit against Nanomics Biotechnology to defend its nanoparticle-enrichment patents, while continuing large operating losses near $70-100M annually.

Name

Seer

Legal name

Seer, Inc.

Website

https://seer.bio

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Seer is a public proteomics company (NASDAQ: SEER) that sells the Proteograph Product Suite, an integrated nanoparticle-based platform combining assay kits, automation instruments, and cloud software for deep plasma proteome profiling. It serves academic translational researchers, biopharma development teams, and biomarker discovery programs through direct sales, STAC services, and a global CRO network.

Ownership category

akta.pro rank

Product category

Proteomics Instrumentation and Consumables

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Material Characterization & Spectroscopy (NMR/FTIR/MS) (HLAGADAK)

Keywords

• Proteomics platform
• Plasma proteomics
• Mass spectrometry
• Protein biomarker discovery
• Nanoparticle protein enrichment

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Instruments (SP100, SP200, SP200t): Capital equipment sales of automation instruments for proteomics sample preparation, sold with 12-month warranties and optional extended service plans. Title passes to customer upon shipment.
2. Consumables (Assay Kits): Recurring revenue from single-use assay kits including Proteograph ONE, XT, and DIRECT assays, consisting of nanoparticles and reagents. Consumables must be purchased alongside instruments and are single-use only.
3. Software Licenses (ICS, PAS): Software licenses for instrument control (ICS) and data analysis (PAS) provided in object code, bundled with instrument purchase and maintained during warranty period.
4. STAC Services: Fee-for-service proteomics analysis through Seer Technology Access Center, providing end-to-end sample processing, mass spectrometry, and bioinformatics for customers without in-house capabilities.
5. Service Provider Network: CRO partners provide proteomics services using Seer technology, creating distributed service revenue ecosystem across global regions.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels7 records

Core offering

Seer provides the Proteograph Product Suite, an integrated proteomics platform that uses proprietary engineered magnetic-core nanoparticles to form reproducible protein coronas from biofluids (primarily plasma), compressing dynamic range to enable deep, unbiased proteome coverage by mass spectrometry. The suite comprises consumable assay kits (Proteograph ONE, XT, DIRECT), the SP200 automation instrument, and the cloud-based Proteograph Analysis Suite (PAS) software. Customers can access the technology via in-house instrument purchase, the Seer Technology Access Center (STAC) fee-for-service, or through a global network of CRO service providers and Centers of Excellence.

Product overview

Seer offers the Proteograph Product Suite as an integrated proteomics platform. The core offering consists of engineered nanoparticle-based assay kits (Proteograph ONE Assay, Proteograph DIRECT Assay), the SP200 Automation Instrument for automated sample preparation, and the Proteograph Analysis Suite (PAS) cloud software for data analysis. Customers can access the technology through instrument purchase (in-house), the Seer Technology Access Center (STAC) managed service, or through certified service providers/CROs. The platform enables deep plasma proteome coverage, identifying up to 10x more proteins than traditional workflows.

Differentiator

Problem solved

Functional benefit

Brands

• Proteograph Product Suite: Complete proteomics workflow including Proteograph ONE Assay, SP200 Automation Instrument, and Proteograph Analysis Suite for deep, unbiased plasma proteome analysis
• STAC (Seer Technology Access Center)
• Proteograph Analysis Suite (PAS)
• Seer Insights Program

Products and services

• Proteograph Product Suite Integrated proteomics workflow combining engineered nanoparticle assay kits, the SP200 automation instrument, and cloud-based analysis software for deep, unbiased, large-scale plasma proteome profiling for academic, biotech, pharma, and government researchers.
• Proteograph ONE Assay Single-use high-throughput assay kit for deep, reproducible, unbiased proteomic analysis that processes up to 80 samples at a time with one MS injection per sample, for population-scale proteomics studies.
• Proteograph DIRECT Assay

Quantifiable outcome

• Identifies up to 10x more protein groups than direct digest (neat) plasma methods
• +5 more outcomes

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature9 records

Partnerships

15 partnerships are on record, tiered core, minor, strategic and regional.

• Korea UniversitycoreStrategic or Co-development Partner · 22 June 2026Collaboration to advance AI-driven plasma proteomics for multi-cancer screening. Preliminary data presented at ASMS 2026 analyzing 5,500+ plasma samples across ten cancer types. Ongoing collaboration expected to analyze more than 20,000 clinical plasma samples total.
• Brigham and Women's HospitalcoreStrategic or Co-development Partner · 29 May 2026Co-complainant with Seer in ITC complaint against Nanomics Biotechnology. Licensor of nanoparticle protein enrichment patent. Long-standing research collaborator with CEO Omid Farokhzad having served as Professor at Harvard Medical School directing the Center for Nanomedicine at Brigham and Women's Hospital.
• Nanomics Biotechnology Co., Ltd.minorOthers · 29 May 2026Respondent in patent infringement complaint filed at ITC and federal district court. Seer seeking exclusion order to bar Nanomics' Proteonano kits and workstations from US market for alleged infringement of five U.S. patents.
• Precision Health Research, Singapore (PRECISE)coreStrategic or Co-development Partner · 13 May 2026Collaboration to provide proteomics analysis on 10,000 samples for landmark population-scale study. Integration with PRECISE-SG100K biobank initiative advancing population-scale proteomics research.
• RetinalGenix TechnologiesstrategicStrategic or Co-development Partner · 16 October 2025Collaboration to develop early detection biomarkers for neurodegenerative, systemic, and retinal diseases by combining retinal imaging with proteomic profiling. Partnership aims to identify molecular biomarkers before clinical symptoms appear.
• Thermo Fisher ScientificcoreTechnology or Integration · 16 October 2025STAC service center uses Thermo Scientific Orbitrap Astral and Orbitrap Exploris 480 mass spectrometers, Vanquish Neo and Ultimate 3000 LC systems, and Pharmafluidics µPAC columns for proteomics analysis services.
• BrukercoreTechnology or IntegrationSTAC service center uses Bruker timsTOF HT and timsTOF SCP mass spectrometers with nanoElute and Ultimate 3000 LC systems. Note: Bruker subsidiaries (PreOmics, Biognosys) are also pursuing patent challenges against Seer.
• SciexcoreTechnology or IntegrationSTAC service center uses Sciex ZenoTOF 7600 mass spectrometer for proteomics analysis services.
• EvoteccoreChannel Partner/ Reseller/ DistributorEuropean CRO partner operating high-throughput multi-omics platform EVOpanOmics with >100,000 samples/year capacity using Seer Proteograph technology. Partner since 2022, expanding use beyond serum/plasma to CSF, urine, secretome and other biofluids.
• Soulbrain HoldingsregionalChannel Partner/ Reseller/ DistributorAsia Pacific channel partner (Korea) with domestic Proteograph platform business. Secured partnership in Q1 2022 and launched premier services in Korea for broad-scale proteomic profiling.
• Panome BioregionalChannel Partner/ Reseller/ DistributorNorth American CRO service provider and Center of Excellence offering next-generation proteomics using Seer technology. Featured collaborator in Seer webinar programming.
• Discovery Life SciencesregionalChannel Partner/ Reseller/ DistributorGlobal biospecimen and specialty lab services provider offering proteomics using Seer technology for biomarker discovery and clinical trials.
• Cedars-Sinai Precision Biomarker LaboratoriesregionalChannel Partner/ Reseller/ DistributorCommercial CRO wholly owned by Cedars-Sinai Medical Center offering comprehensive proteomics services using Seer technology for precision medicine research.
• Sanford Burnham PrebysregionalChannel Partner/ Reseller/ DistributorAcademic proteomics core facility and Center of Excellence using Seer Proteograph Product Suite with three mass spectrometry platforms and automated sample preparation.
• AllumiqsregionalChannel Partner/ Reseller/ DistributorNorth American CRO partner dedicated to multiomics-driven solutions for biotech and biopharma researchers using Seer sample preparation tools and mass spectrometry services.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/seerbio
• Xx.com/seer_bio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seer